Health care use and primary prophylaxis with colony-stimulating factors

Value in Health

Volumn 14, Issue 2, 2011, Pages 247-252

  Sullivan, Sean D ^a,c   Ramsey, Scott D ^a   Blough, David K ^c   McDermott, Cara L ^a   Clarke, Lauren ^b   McCune, Jeannine S ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Cornerstone Systems Northwest ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer; Colony stimulating factors; Health care use; Supportive care

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; COHORT ANALYSIS; COLORECTAL CANCER; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 79959617223     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.09.005     Document Type: Article

References (29)

1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
2. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8. (Pubitemid 19048173)
3. Riikonen P, Saarinen UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo-controlled study in children. Pediatr Infect Dis J 1994;13:197-202. (Pubitemid 24090307)
4. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24. (Pubitemid 40563265)
5. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-6.
6. Donnelly JP. Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. J Antimicrob Chemother 1993;31:813-29. (Pubitemid 23218145)
7. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997;15:2981-95. (Pubitemid 27330027)
8. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998; 16:3179-90. (Pubitemid 28417441)
9. Bokemeyer C, Kuczyk MA, Kohne H, et al. Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 1996;72:1-9. (Pubitemid 26049813)
10. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716-24.
11. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84. (Pubitemid 46202274)
12. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, v.1. 2009. Available from: Http://www.nccn.org/professionals/physician- gls/f-guidelines.asp. [Accessed October 16, 2009].
13. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. (Pubitemid 46638957)
14. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53. (Pubitemid 44442936)
15. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8. (Pubitemid 32060887)
16. Hershman D, Hurley D, Wong M, et al. Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ 2009;12:203-10.
17. Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. Clin Ther 2009;31:1069-81.
18. Puget Sound Cancer Surveillance System. CSS Reports, Publications, and FAQs. 2009. Available from: Http://www. fhcrc.org/science/phs/css/publications. html. [Accessed October 16, 2009].
19. Cross PB. Premera Blue Cross Company Fact Sheet. 2008. Available from: Https://www.premera.com/stellent/groups/ public/documents/xcpproject/abt- company-fact-sheet.asp.
20. Regence Blue Shield. 2006 Annual Report. 2006. Available from: Http://www.regence.com/about/annualReport/annualreport. jsp. [Accessed October 16, 2009].
21. Washington State Health Recovery Services Administration. Health and Recovery Services Clients. 2009. Available from: Http://maa.dshs.wa.gov/News/ HRSAClients.htm. [Accessed October 16, 2009].
22. Centers for Medicare and Medicaid Services. Medicare Program-General Information. 2005. Available from: Http:// www.cms.hhs.gov/MedicareGenInfo/. [Accessed October 15, 2009].
23. Ramsey S, McCune J, Blough D, et al. Colony stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 2010;16:678-86.
24. U.S. Food and Drug Administration. Food and Drug Administration: National Drug Code Directory. 2009. Available from: Http://www.accessdata.fda.gov/ scripts/cder/ ndc/default.cfm. [Accessed October 19, 2009].
25. Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-104.
26. Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009;12:217-25.
27. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-22. (Pubitemid 30205386)
28. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-9. (Pubitemid 30485668)
29. Gelman R, Taylor S. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404-13. (Pubitemid 15179542)